These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 9109912)

  • 1. Striatal dopamine nerve terminal markers but not nigral cellularity are reduced in spinocerebellar ataxia type 1.
    Kish SJ; Guttman M; Robitaille Y; el-Awar M; Chang LJ; Levey AI
    Neurology; 1997 Apr; 48(4):1109-11. PubMed ID: 9109912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regional and temporal expression of the peripheral benzodiazepine receptor in MPTP neurotoxicity.
    Kuhlmann AC; Guilarte TR
    Toxicol Sci; 1999 Mar; 48(1):107-16. PubMed ID: 10330690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users.
    Wilson JM; Levey AI; Bergeron C; Kalasinsky K; Ang L; Peretti F; Adams VI; Smialek J; Anderson WR; Shannak K; Deck J; Niznik HB; Kish SJ
    Ann Neurol; 1996 Sep; 40(3):428-39. PubMed ID: 8797532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of dopamine uptake sites and dopamine D2 receptors in striatonigral degeneration.
    González AM; Berciano J; Figols J; Pazos A; Pascual J
    Brain Res; 2000 Jan; 852(1):228-32. PubMed ID: 10661519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of [3H]WIN 35,428 binding, a marker for dopamine transporter, in embryonic mesencephalic neuronal cultures with striatal membranes of adult rats.
    Valchar M; Hanbauer I
    J Neurochem; 1993 Feb; 60(2):469-76. PubMed ID: 8419533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease.
    Wilson JM; Levey AI; Rajput A; Ang L; Guttman M; Shannak K; Niznik HB; Hornykiewicz O; Pifl C; Kish SJ
    Neurology; 1996 Sep; 47(3):718-26. PubMed ID: 8797470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine transporters are markedly reduced in Lesch-Nyhan disease in vivo.
    Wong DF; Harris JC; Naidu S; Yokoi F; Marenco S; Dannals RF; Ravert HT; Yaster M; Evans A; Rousset O; Bryan RN; Gjedde A; Kuhar MJ; Breese GR
    Proc Natl Acad Sci U S A; 1996 May; 93(11):5539-43. PubMed ID: 8643611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term methamphetamine-induced decreases of [(11)C]WIN 35,428 binding in striatum are reduced by GDNF: PET studies in the vervet monkey.
    Melega WP; Lacan G; Desalles AA; Phelps ME
    Synapse; 2000 Mar; 35(4):243-9. PubMed ID: 10657033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vesicular neurotransmitter transporters in Huntington's disease: initial observations and comparison with traditional synaptic markers.
    Suzuki M; Desmond TJ; Albin RL; Frey KA
    Synapse; 2001 Sep; 41(4):329-36. PubMed ID: 11494403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased densities of dopamine and serotonin transporters and of vesicular monoamine transporter 2 in severely kainic acid lesioned subregions of the striatum.
    Naudon L; Leroux-Nicollet I; Boulay D; Costentin J
    J Neural Transm (Vienna); 2001; 108(4):431-44. PubMed ID: 11475010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding domains for blockers and substrates on the dopamine transporter in rat striatal membranes studied by protection against N-ethylmaleimide-induced reduction of [3H]WIN 35,428 binding.
    Xu C; Coffey LL; Reith ME
    Naunyn Schmiedebergs Arch Pharmacol; 1997 Jan; 355(1):64-73. PubMed ID: 9007844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of dopaminergic drugs on the in vivo binding of [3H]WIN 35,428 to central dopamine transporters.
    Scheffel U; Steinert C; Kim SE; Ehlers MD; Boja JW; Kuhar MJ
    Synapse; 1996 Jun; 23(2):61-9. PubMed ID: 8723710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [3H]WIN 35,428 ([3H]CFT) binds to multiple charge-states of the solubilized dopamine transporter in primate striatum.
    Gracz LM; Madras BK
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1224-34. PubMed ID: 7791095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat.
    Wilson JM; Kish SJ
    J Neurosci; 1996 May; 16(10):3507-10. PubMed ID: 8627383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration.
    Connor B; Kozlowski DA; Unnerstall JR; Elsworth JD; Tillerson JL; Schallert T; Bohn MC
    Exp Neurol; 2001 May; 169(1):83-95. PubMed ID: 11312561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine transport: pharmacological distinction between the synaptic membrane and the vesicular transporter in rat striatum.
    Rostène W; Boja JW; Scherman D; Carroll FI; Kuhar MJ
    Eur J Pharmacol; 1992 Jul; 218(1):175-7. PubMed ID: 1397029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease.
    Lee CS; Samii A; Sossi V; Ruth TJ; Schulzer M; Holden JE; Wudel J; Pal PK; de la Fuente-Fernandez R; Calne DB; Stoessl AJ
    Ann Neurol; 2000 Apr; 47(4):493-503. PubMed ID: 10762161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Striatal dopaminergic abnormalities in human cocaine users.
    Little KY; Zhang L; Desmond T; Frey KA; Dalack GW; Cassin BJ
    Am J Psychiatry; 1999 Feb; 156(2):238-45. PubMed ID: 9989560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Halogenated mazindol analogs as potential inhibitors of the cocaine binding site at the dopamine transporter.
    Houlihan WJ; Boja JW; Parrino VA; Kopajtic TA; Kuhar MJ
    J Med Chem; 1996 Dec; 39(25):4935-41. PubMed ID: 8960553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in dopamine availability in the nigrostriatal and mesocortical dopaminergic systems by gait in Parkinson's disease.
    Ouchi Y; Kanno T; Okada H; Yoshikawa E; Futatsubashi M; Nobezawa S; Torizuka T; Tanaka K
    Brain; 2001 Apr; 124(Pt 4):784-92. PubMed ID: 11287377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.